跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 700 条关于
“nmCRPC”
全部
700
临床试验
620
药物
8
机构
0
资讯
72
去年
Darolutamide Demonstrates Superior Benefits in Black and White Patients with Non-Metastatic Prostate Cancer
3年前
BDR Pharmaceutical Launches First Generic Apalutamide in India for Prostate Cancer Treatment
去年
Apalutamide Demonstrates Superior Overall Survival Compared to Enzalutamide in mCSPC
7个月前
ERLEADA Shows 51% Reduction in Death Risk Versus Darolutamide in Real-World Prostate Cancer Study
去年
Bayer Seeks FDA Approval to Expand Nubeqa's Indication for Metastatic Hormone-Sensitive Prostate Cancer
去年
Bayer Seeks Approval in China for Darolutamide to Treat Metastatic Hormone-Sensitive Prostate Cancer
2年前
Darolutamide Plus ADT Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer
4年前
Bayer Seeks Expanded Approval for Darolutamide in Japan and China for Metastatic Hormone-Sensitive Prostate Cancer
3年前
MHRA and NHS England Fast-Track Novel Prostate Cancer Treatment Darolutamide Combination Therapy
6个月前
JAMP Pharma Group Launches Generic Enzalutamide for Prostate Cancer Treatment in Canada
第 1 页,共 8 页
上一页
下一页